Abstract
Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Redu ctase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs.
Keywords: Benign prostatic hyperplasia, a1α-adrenoceptor antagonists, 5α-reductase inhibitors
Current Medicinal Chemistry
Title: Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
Volume: 13 Issue: 28
Author(s): Katarzyna Kulig and Barbara Malawska
Affiliation:
Keywords: Benign prostatic hyperplasia, a1α-adrenoceptor antagonists, 5α-reductase inhibitors
Abstract: Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Redu ctase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs.
Export Options
About this article
Cite this article as:
Kulig Katarzyna and Malawska Barbara, Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia, Current Medicinal Chemistry 2006; 13 (28) . https://dx.doi.org/10.2174/092986706779010315
DOI https://dx.doi.org/10.2174/092986706779010315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry A Brief Overview on Chemistry and Biology of Benzoxepine
Letters in Drug Design & Discovery Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Treatment of ADHD and the Short and Long Term Effects on Sleep
Current Pharmaceutical Design The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Molecular Basis of Adrenomedullin 1 Receptor Function and Its Roles in the Cardiovascular System
Current Hypertension Reviews Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry Comparative Bioavailability of Two Oral Formulations of Clozapine in Steady State Administered in Schizophrenic Volunteers Under Individualized Dose Regime
Current Clinical Pharmacology Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry The Roles of Corticotropin Releasing Factor (CRF) in Responses to Emotional Stress: Is CRF Release a Cause or Result of Fear/Anxiety?
CNS & Neurological Disorders - Drug Targets Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology